Immune System News and Research

RSS

NY-ESO-1 recombinant proteins to be used in clinical trials for treating melanoma and ovarian cancer

The Bioproduction Facility at Cornell University has produced the first batch of NY-ESO-1 recombinant protein-a cancer vaccine-that will be used in clinical trials for patients facing either ovarian cancer or melanoma. The facility was developed as a partnership between The Ludwig Institute for Cancer Research and Cornell University.

21 Aug 2009

New discovery on cellular fusion

Success in soccer sometimes comes with "bending it like Beckham." Success in cellular fusion - as occurs at the moment of conception and when nerve cells exchange neurotransmitters - requires that a membrane be bent before the merging process can begin, University of Wisconsin-Madison researchers have shown.

20 Aug 2009

IBISS research group's project aims to examine Ribavirin role in promoting the survival of transplanted stem cells

Hard to Treat Diseases (HTDS.PK) Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer Slavica BioChem reported that IBISS research group from Serbia has begun preliminary experiments within a project aimed at Promoting stem cell graft survival in the model of traumatic brain injury in rats.

20 Aug 2009

Advaxis awarded $210,000 for development of a dual antigen vaccine

Advaxis, Incorporated (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, has been awarded a $210,000 grant from the US National Institute of Health (NIH) to develop a single bioengineered Lm vaccine to deliver two different antigen-adjuvant proteins.

20 Aug 2009

Fluxion Biosciences receives a $1.8 million NIH grant for developing microfluidic platform

Fluxion Biosciences, a leading developer of microfluidic systems for functional cell analysis, today announced that it has received a $1.8 million NIH grant for the development of a high-throughput screening platform for anti-microbial drug discovery.

From Fluxion Biosciences 20 Aug 2009

Scientists find another mechanism that destroys tumor cells

Cells don't like to be alone. In the early stages of tumor formation, a cell might be pushed out of its normal home environment due to excessive growth. But a cell normally responds to this homeless state by dismantling its nucleus, packing up its DNA, and offering itself to be eaten by immune system cells. Simply put, the homeless cell kills itself. This process, known as apoptosis, typically stops potential cancer cells before they have a chance to proliferate.

20 Aug 2009

UT Southwestern Medical Center: Human gut bacteria ward off Toxoplasma gondii

Immunology researchers at UT Southwestern Medical Center have found that bacteria present in the human gut help initiate the body's defense mechanisms against Toxoplasma gondii, the parasite responsible for toxoplasmosis.

20 Aug 2009

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Inovio Biomedical Corporation (NYSE AMEX: INO) (“Inovio”) today reported financial results for the three and six months ended June 30, 2009. Total revenue of $2.5 million and $2.9 million for the three and six months ended June 30, 2009, compared to $663,000 and $1.3 million for the three and six months ended June 30, 2008, respectively.

20 Aug 2009

Reliv International's chief scientific officer suggests tips to improvise lifestyle as age increases

According to the Centers for Disease Control and Prevention, the United States is on the "brink of a longevity revolution." In fact, by 2030, one in every five Americans will be over the age of 65. So, what can adults do now to ensure that they continue to enjoy a great lifestyle in their later years? In honor of Healthy Aging Month this September, Dr. Carl Hastings, chief scientific officer of Reliv International, offers some advice.

20 Aug 2009

Steroid hormones found to affect gene activity

Intermittent signaling by steroid hormones can affect the way genes are expressed in rodents, according to research by scientists at the University of Bristol and the National Cancer Institute (NCI), USA. This work has major implications for understanding how steroids work and opens novel avenues for new therapies.

19 Aug 2009

The Gambia introduces pneumococcal immunisation programme

The Gambia, Minister of Health Dr. Mariatou Jallow administered the first dose of the pneumococcal vaccine to Gambian children at a rural clinic outside Banjul today. Joined by the Gambia’s Vice President, Mrs. Isatou Njie-Saidy, Dr. Jallow and hundreds of Gambian citizens celebrated this historic event, which marks the first step in the rollout of the Gambia’s national pneumococcal immunisation programme.

19 Aug 2009

H1N1 vaccine orders top 1 billion, WHO Says

"Northern hemisphere countries have so far ordered more than one billion doses of swine flu vaccine, the World Health Organisation said Tuesday, sparking warnings over shortages," Agence France-Presse reports. While some countries, including Greece, The Netherlands, Canada and Israel, have ordered enough vaccine to inoculate their citizens, "[o]thers, such as Germany, the United States, Britain and France, have put in orders that would cover between 30 and 78 percent of people," the news service writes.

19 Aug 2009

U.S. FDA approval of miconazole MBT represents a significant milestone for Strativa Pharmaceuticals

Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad((R)) mucoadhesive buccal tablets (MBT) to treat oropharyngeal candidiasis (OPC).

19 Aug 2009

ImmunoCellular Therapeutics to participate in the Southern California Investor Conference

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it will participate in the Southern California Investor Conference being held in Newport Beach, CA, on Tuesday August 18, 2009.

19 Aug 2009

CEL-SCI expands work on current H1N1 virus vaccine

CEL-SCI Corporation has announced that it is expanding the scope of its work towards creating a novel treatment and vaccination against the current H1N1 virus, as well as a future mutated form in which the virus has acquired greater morbidity and mortality.

19 Aug 2009

BioAlliance Pharma's new drug application for oropharyngeal candidiasis treatment accepted by the FDA

BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad® (Loramyc®) Mucoadhesive Buccal Tablets (MBT) to treat oropharyngeal candidiasis (OPC). Miconazole Lauriad® delivers the antifungal miconazole via a mucoadhesive buccal tablet that is designed to enable once-daily dosing of the active ingredient at the site of infection.

19 Aug 2009

Research study highlights the biological importance of Vitamin D in humans and other primates

A new study has concluded that one key part of the immune system, the ability of vitamin D to regulate anti-bactericidal proteins, is so important that is has been conserved through almost 60 million years of evolution and is shared only by primates, including humans - but no other known animal species.

19 Aug 2009

CSL Biotherapies to supply Afluria influenza vaccines from newly licensed packaging facility

CSL Biotherapies, a subsidiary of CSL Limited, one of the world's leading manufacturers of influenza vaccine, announced today that the U.S. Food and Drug Administration (FDA) has licensed the company’s newest vaccine filling and packaging facility, located in Kankakee, Ill. The facility, part of an investment to expand CSL’s U.S. influenza vaccine production capabilities, includes a high-speed, single-dose vaccine syringe filling line.

19 Aug 2009

New understanding on meningitis cause

A specific protein on the surface of a common bacterial pathogen allows the bacteria to leave the bloodstream and enter the brain, initiating the deadly infection known as meningitis. The new finding, which may guide development of improved vaccines to protect those most vulnerable, including young infants and the elderly, is now available online in the Journal of Experimental Medicine.

19 Aug 2009

New production technology to develop vaccine for norovirus

Scientists have used a new vaccine production technology to develop a vaccine for norovirus, a dreaded cause of diarrhea and vomiting that may be the second most common viral infection in the United States after the flu. Sometimes called the "cruise ship virus," this microbe can spread like wildfire through passenger liners, schools, offices and military bases.

19 Aug 2009

Immune System News and Research

NY-ESO-1 recombinant proteins to be used in clinical trials for treating melanoma and ovarian cancer

New discovery on cellular fusion

IBISS research group's project aims to examine Ribavirin role in promoting the survival of transplanted stem cells

Advaxis awarded $210,000 for development of a dual antigen vaccine

Fluxion Biosciences receives a $1.8 million NIH grant for developing microfluidic platform

Scientists find another mechanism that destroys tumor cells

UT Southwestern Medical Center: Human gut bacteria ward off Toxoplasma gondii

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Reliv International's chief scientific officer suggests tips to improvise lifestyle as age increases

Steroid hormones found to affect gene activity

The Gambia introduces pneumococcal immunisation programme

H1N1 vaccine orders top 1 billion, WHO Says

U.S. FDA approval of miconazole MBT represents a significant milestone for Strativa Pharmaceuticals

ImmunoCellular Therapeutics to participate in the Southern California Investor Conference

CEL-SCI expands work on current H1N1 virus vaccine

BioAlliance Pharma's new drug application for oropharyngeal candidiasis treatment accepted by the FDA

Research study highlights the biological importance of Vitamin D in humans and other primates

CSL Biotherapies to supply Afluria influenza vaccines from newly licensed packaging facility

New understanding on meningitis cause

New production technology to develop vaccine for norovirus

Understanding the DNA Damage Response in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News